Table 1.
Clinical characteristics of included DCCT/EDIC Study participants with and without kidney disease
| Kidney disease status* | ||
| Controls (N=43) | Cases (N=43) | |
| Clinical characteristics | ||
| Demographic data | ||
| Age (years) | 50 (8) | 51 (9) |
| Duration of diabetes (years) | 30 (5) | 30 (6) |
| Female gender | 20 (47) | 17 (40) |
| DCCT intensive therapy | 21 (49) | 14 (33) |
| DCCT primary cohort | 22 (51) | 22 (51) |
| Physical examination data | ||
| Body mass index (kg/m2) | 29.3 (5.2) | 30.4 (6.0) |
| Systolic BP (mmHg) | 122 (14) | 137 (21) |
| Diastolic BP (mmHg) | 75 (9) | 76 (13) |
| Laboratory data | ||
| eGFR (mL/min/1.73 m2) | 103 (9) | 39 (14) |
| Albumin excretion rate (mg/day) | 10 (7) | 1978 (2914) |
| Current HbA1c (%) | 8.0 (1.0) | 8.6 (1.7) |
| DCCT/EDIC time-weighted HbA1c (%) | 7.9 (0.6) | 9.2 (1.1) |
| EDIC time-weighted HbA1c (%) | 7.9 (0.7) | 9.1 (1.3) |
| LDL cholesterol (mg/dL) | 95 (29) | 105 (39) |
| HDL cholesterol (mg/dL) | 60 (19) | 52 (18) |
| Triglycerides (mg/dL) | 77 (35) | 131 (73) |
Cell contents are mean (SD) or N (%).
*Cases were defined by incident persistent eGFR <60 mL/min/1.73 m2 with urinary AER >300 mg/24 hour; control subjects were randomly selected from the pool of DCCT/EDIC Study participants who maintained persistent eGFR >90 mL/min/1.73 m2 and AER <30 mg/24 hour through the study visit on which the corresponding case participant developed incident eGFR <60 mL/min/1.73 m2 and were additionally matched to cases on duration of diabetes and DCCT cohort.
AER, albumin excretion rate; BP, blood pressure; DCCT/EDIC, Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HbA1c, hemoglobin A1c; LDL. low-density lipoprotein.